Latest in News & Research

Four-Year Efficacy and Safety Of Continuous Secukinumab in HS: SUNSHINE/SUNRISE Core and Extension Trials

By Authors: Martina L. Porter, Christos C. Zouboulis, Falk G. Bechara, Alice B. Gottlieb, Ziad Reguiaï, Valeria Jordan M., Betrand Paguet, Artem Zharkov, Vipin N., Alexa B. Kimball

Early Treatment Initiation With Secukinumab: Insights From the SUNSHINE/SUNRISE Core Trials

By Authors: Amit Garg, Christopher J. Sayed, Martina L. Porter, Haley B. Naik, Hebing Wang, Alexis Shew, Valeria Jordan M., John R. Ingram, Antonio Martorell

Vixarelimab Demonstrates Sustained Dose-Dependent Benefits for Prurigo Nodularis

Significant reduction seen in the mean Worst Itch Numeric Rating Scale scores for high-, mid-, low-dose vixarelimab versus placebo

By Dermsquared Editorial Team | | December 23, 2025

New Sunscreen Ingredient Could Soon Be Allowed in the U.S.

The U.S. Food and Drug Administration is reviewing bemotrizinol, a sunscreen ingredient used widely overseas

By India Edwards (HealthDay News) | | December 22, 2025

Study Explores the Etiology of Melanoma Associated With Tanning Bed Usage

Tanning bed users more likely to have melanoma on body sites with low cumulative levels of sun damage, to have multiple melanomas

By Elana Gotkine (HealthDay News) | | December 22, 2025

Flipped Dose Nivolumab + Ipilimumab Beneficial in Advanced Unresectable Melanoma

Adjusted hazard ratio for progression-free and overall survival significantly lower for NIVO3+IPI1 versus NIVO1+IPI3

By Dermsquared Editorial Team | | December 22, 2025

Causal Effect Suggested for BMI, IBD on Hidradenitis Suppurativa

Mendelian randomization analyses support effect of BMI and IBD, with no signs of pleiotropy

By Dermsquared Editorial Team | | December 22, 2025

Botulinum Toxin Safe, Effective for Refractory Digital Ischemia

High rates of complete response seen for ischemia, ulcers, gangrene; adverse events occurred infrequently

By Dermsquared Editorial Team | | December 12, 2025

Long-Term Durable Responses to Cemiplimab Seen in Advanced CSCC

Of four patients receiving retreatment with cemiplimab, three remained progression-free at data cutoff

By Dermsquared Editorial Team | | December 12, 2025

Rocatinlimab Yields Significant Improvements in Atopic Dermatitis

Significant improvements seen in coprimary end points of EASI-75 response and vIGA-AD score of 0 or 1 versus placebo

By Elana Gotkine (HealthDay News) | | December 12, 2025

RSNA: Ultrasound Findings Can ID Cosmetic Filler-Linked Vascular Adverse Events

With ultrasound findings, the exact place where the occlusion occurs can be targeted

By Elana Gotkine (HealthDay News) | | December 12, 2025

CatBoost Model Has Best Performance for Predicting Survival in Melanoma

Model achieved area under the curve values of 0.7577, 0.7595, and 0.7557 for one-, three-, and five-year survival predictions

By Dermsquared Editorial Team | | December 11, 2025

Dermatoscopes Compared for Dermoscopy Performance, Teledermatology Use

Ambient light and polarized dermatoscopes both enable dermoscopy performance and receipt of teledermatology recommendations

By Dermsquared Editorial Team | | December 11, 2025

FDA Approves Updated Label for Unloxcyt

Approval is for adults with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or curative radiation

By Lori Solomon (HealthDay News) | | December 11, 2025

Pooled Phase 3 Data From CSU Trials

By Authors: Sarbjit Saini, Giselle Mosnaim, Ana Giménez-Arnau, Linfeng Li, El-Djouher Martzloff, Alis Burciu, Karine Lheritier, Martin Metz

CSU Disease Activity Data From a Phase 3 Trial

By Authors: Martin Metz, Ana M. Giménez-Arnau, Petra Staubach, Marta Ferrer Puga, Kanokvalai Kulthanan, Xinghua Gao, Karine Lheritier, Christine-Elke Ortmann, Nadine Chapman-Rothe, Sibylle Haemmerle, Atsushi Fukunaga, Michihiro Hide

Slight Increase in Global Burden of Psoriasis Seen Through 2021

Age-standardized incidence rate projected to continue increasing through 2050 in males and females based on data through 2021

By Dermsquared Editorial Team | | November 26, 2025

Melanoma Incidence Has Decreased Among Young Men in the United States

Decline in melanoma incidence seen among men, but not women younger than 40 years; no difference seen between older men and women

By Dermsquared Editorial Team | | November 26, 2025

Chronic Pruritus Prevalent Among Older Adults

Atopic dermatitis and psychological symptoms were associated with greatest impairment in pruritus-specific QoL

By Elana Gotkine (HealthDay News) | | November 26, 2025

Introducing Amy Jones and PANP360: A New Era for PAs and NPs in Dermatology

PANP360 brings dermatology PAs and NPs a place to learn, connect, and grow—clinically and as whole people.

By Dermsquared Editorial Team | | November 20, 2025

Prevalence of Primary Epithelioid Sarcoma Is 0.49 per 100,000 in the U.S.

Prevalence was highest among Whites, lowest among American Indians; highest prevalence seen for those aged 35 to 39 years

By Dermsquared Editorial Team | | November 19, 2025

Study Compares Treatment Modalities for Management of Keloids

Intralesional triamcinolone acetonide had greatest efficacy, with relatively favorable side effect profile

By Dermsquared Editorial Team | | November 19, 2025

Melanoma Clusters Identified in Pennsylvania Counties Near Farmland

Increase in cultivated land and herbicide-treated acreage independently linked to increase in melanoma incidence

By Elana Gotkine (HealthDay News) | | November 19, 2025

24 of 1200

Headline from the Week of February 09 - 15, 2026

Second Annual National Cancer Database Report Presented for 2022

By Elana Gotkine (HealthDay News) | | February 11, 2026

Presurgical Pembrolizumab Beneficial for Desmoplastic Melanoma

By Elana Gotkine (HealthDay News) | | February 11, 2026